MedPath

Optical coherence tomography tissue tissue typing - Clinical validatio

Completed
Conditions
Atherosclerose
10011082
Registration Number
NL-OMON36438
Lead Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

Patient eligible for percutaneous coronary intervention (PCI) of a native coronary artery
Study vessel must be accessible to the OCT and Lipiscan/IVUS catheters
Study vessel has at least 20 mm of native artery wall with analyzable OCT image quality
Informed consent

Exclusion Criteria

Unable to provide informed consent
Hemodynamic instability
Cardiogenic shock
TIMI 0 flow at target lesion site
Lesion beyond acute bends or in a location within the coronary anatomy where the catheter cannot traverse
Bypass graft as target vessel
Ejection fraction less than 30%
Contra-indication to emergency coronary artery bypass surgery
No access to cardiac surgery
Contra-indication to treatment with aspirin, ticlopidine, clopidogrel, prasugrel or heparin
Renal insufficiency (creatinine clearing < 50ml/min)
Pregnancy or inadequate anticonception

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary endpoint of the study is a quantification of the performance of<br /><br>OC3T as a tissue type imaging tool. This quantification will entail calculation<br /><br>of sensitivity and specificity of the optical attenuation as measured by OCT<br /><br>for three different categories: lipid-rich/necrotic core plaque, macrophage<br /><br>infiltrated regions, and fibrous/calcified tissues. Matched cross-sections will<br /><br>be scored for tissue type in quadrants in Lipiscan/IVUS and macrophage score<br /><br>from OCT variance analysis. These scores will be correlated with optical<br /><br>attenuation measured by OCT. This endpoint will be assessed on a per vessel<br /><br>basis and in the entire data set overall.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>OCT<br /><br>Mean, maximal and minimal lumen diameter (mm);<br /><br>Number of lesions, defined as a % diameter stenosis (%DS) >20%. %DS is<br /><br>calculated as (1-MLD/RD)x100, where MLD is minimal lumen diameter, and RD is<br /><br>reference diameter.<br /><br>Lesion type according to published criteria;<br /><br>Lesion composition derived from OC3T processing;<br /><br>If a cap can be identified, minimum cap thickness.<br /><br>Lipiscan/IVUS<br /><br>Calcium deposits from IVUS;<br /><br>Lipid-core plaques from Lipiscan;<br /><br>Lumen area, vessel area, and plaque burden at 1 mm intervals from IVUS.<br /><br>QCA<br /><br>Mean, maximal and minimal lumen diameter (mm).</p><br>
© Copyright 2025. All Rights Reserved by MedPath